Shellback Capital’s DexCom DXCM Stock Holding History

Shellback Capital’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-100,000	Closed	-$8.73M	–	119
2025 Q2	$8.73M	Buy	+100,000	New	+$7.84M	0.58%	61

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Shellback Capital's DXCM Position: Q3 2025 in Review

Shellback Capital sold out of DexCom (DXCM) in Q3 2025, closing a stake of 100,000 shares — an estimated $8.73M sold.

Shellback Capital first reported a position in DXCM in Q2 2025 and held it in 1 quarter. The position peaked at $8.73M in Q2 2025. 910 funds tracked by Wall St. Rank hold DXCM as of Q3 2025.

Shellback Capital reported no remaining DexCom position as of Q3 2025 after selling out during the quarter.
Shellback Capital sold 100,000 DexCom shares in Q3 2025, an estimated $8.73M.
Shellback Capital first reported a position in DexCom in Q2 2025 and held it in 1 quarter.
Shellback Capital's DexCom position peaked at $8.73M in Q2 2025.
910 funds tracked by Wall St. Rank held DexCom as of Q3 2025.

Based on Shellback Capital's 13F filing for Q3 2025, filed 14 Nov 2025.